Loading…
DNTH
Dianthus Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology
$105.84-5.11%
Key metrics
- Market cap
- $5.92B
- P/E
- —
- Forward P/E
- —
- P/B
- 4.9x
- Dividend yield
- —
- EPS
- -$4.24
- ROE
- -26.07%
- Profit margin
- 0.00%
- Revenue growth
- +294.30%
- Beta
- 0.08
- 52-week high
- $117.88
- 52-week low
- $23.39
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
- 92
- New York, United States
Company description provided by Yahoo Finance.